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Abstract: Basal cell carcinoma (BCC) is the most common human malignancy. Recent 
advances in our understanding of the critical biologic pathways implicated in the development 
and progression of BCC have led to the development of the first molecular targeted therapy for 
this disease. The hedgehog pathway is mutated in virtually all patients with BCC and recent trials 
with vismodegib, an inhibitor of this pathway, have shown significant responses. This review 
will discuss the importance of the hedgehog pathway in the pathogenesis of BCC and describe 
in detail the pharmacology of vismodegib in relation to its activity in advanced BCC.
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Introduction
Basal cell carcinoma (BCC) is the most common human malignancy. Since it is not always 
included in cancer registries, the true incidence is unknown. It is estimated that approxi-
mately 3.5 million nonmelanoma skin cancers in 2.2 million patients are treated annually 
in the United States, the majority of which are BCC (American Cancer Society, Facts 
and Figures 2013). The American Academy of Dermatology estimates that approximately 
2 million BCC are treated every year (http://www.aad.org/dermatology-a-to-z/diseases-
and-treatments/a---d/basal-cell-carcinoma). Fortunately, these tumors are usually amenable 
to local therapy and only 1%–5.3% of lesions recur after initial resection.1
Interestingly, even locally aggressive tumors seldom metastasize and metastatic 
BCC is quite rare. Since accurate incidence records of this disease are not available, 
the burden of metastatic disease is difficult to ascertain. Rates ranging from 0.0028% to 
0.55% of patients with BCC developing metastases have been reported,2–7 but even 
these have been questioned.8 The median age of patients with metastatic BCC at the 
time of diagnosis of the primary lesion is about 45–56 years, and metastases appear at 
a median of about 9 years later.9–11 Factors that may predispose to the development of 
metastatic BCC include male gender,9 primary lesion in the ear region9,11,12 and face,11 
large11 and locally invasive13 primary tumors, recurrence following initial treatment,11 
and impairment of cell mediated immunity (eg, acquired immunodeficiency syndrome, 
therapeutic immunosuppression).14,15
Recent advances in our understanding of the biologic pathways that appear to be 
important in the development and progression of BCC have led to the development of 
the first molecular targeted therapy for this disease, vismodegib. The hedgehog (Hh) 
pathway is mutated in virtually all patients with BCC and inhibition of this pathway 
with vismodegib appears to result in significant clinical responses. The following 
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sections will discuss the importance of the Hh pathway in the 
pathogenesis of BCC and describe in detail the pharmacology 
of vismodegib in relation to advanced BCC.
Hh pathway and its role in BCC
The Hh pathway is one of the most common signal 
transduction pathways used by mammalian cells16 for normal 
embryonic development of the neural tube, axial skeleton, 
skin, and hair,17 and for wound healing during postnatal life.18 
While this pathway appears to be silenced in most adult 
tissues,19 it has been shown to promote the proliferation of 
stem cells from various tissues in the adult. These include 
hematopoietic cells,20 mammary,21 mesenchymal,22 and 
neural23 stem cells. This pathway also appears to play a 
role in the transition of hair follicles from the resting to the 
growth phase.24 This could explain the alopecia noted in 
patients treated with the Hh pathway inhibitor, vismodegib. 
In addition, this pathway seems to be involved in the repair 
of various organs in the adult following injury.25–27
Recent studies have shown that aberrant Hh signaling 
pathway is involved in the pathogenesis, self-renewal of stem 
cells, and chemotherapeutic resistance of BCC.28,29 Besides 
BCC, Hh signaling is also activated in other malignancies 
such as medulloblastoma,30,31 colon,32 prostate,33,34 breast,35 
lung,36 and various hematologic malignancies.37–40 The Hh 
pathway dependent gene upregulation leads to increased 
cell proliferation and cell survival, and promotes bone 
metastases.41 This pathway has been shown to regulate the 
epithelial–mesenchymal transition and dissemination of 
cancer stem cells in solid tumors,42,43 and enhance metastatic 
disease progression.44 These observations suggest that 
targeted inhibition of Hh signaling may be an effective 
treatment strategy for several human cancers.
The signaling cascade of the Hh pathway in mammalian 
cells is initiated by binding of one of three Hh ligands (sonic, 
Indian, or desert Hh) to the 12 pass transmembrane receptor 
patched 1 (Ptch1) (Figure 1). This causes internalization and 
degradation of Ptch1, thereby releasing smoothened (SMO), 
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Figure 1 A schematic diagram showing inhibition of Hedgehog (Hh) signaling by vismodegib.
Notes: The extracellular Hh ligands (Sonic, Indian, or Desert Hh) bind to Patched 1 (Ptch1), relieving the inhibition of Smoothened (SMO) by Ptch1. SMO disrupts the 
cytoplasmic complex containing the Suppressor of Fused (SUFU)-glioma-associated oncogene homologue (Gli) complex resulting in degradation of Gli3 and translocation of 
Gli1 and Gli2 to the nucleus to upregulate target genes like Ptch1, Gli1, c-Myc, Bcl2, vascular endothelial growth factor, and cyclin D1. Vismodegib binds to the extracellular 
domain of SMO, markedly inhibiting the release and translocation of Gli1 and Gli2 to the nucleus.
Abbreviations: Gli, glioma-associated oncogene homologue; Ptch1, patched 1; SHh, sonic hedgehog; SMO, smoothened; SUFU, Suppressor of Fused; VEGF, vascular 
endothelial growth factor.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
198
Macha et al
Cancer Management and Research 2013:5
a 7 pass transmembrane G protein coupled receptor 
like protein. This protein then enters the primary 
cilia and disrupts the cytoplasmic complex containing 
Suppressor of Fused (SUFU)-glioma-associated oncogene 
homologue (Gli). The SUFU regulates transcriptional 
factors (Glis) through posttranslational modifications like 
phosphorylation, sumoylation, and selective proteolysis.45 
Release of Gli transcription factors (Gli 1–3) from SUFU 
inhibition results in nuclear translocation and upregulation 
of Gli1 associated target genes that include Gli1, Ptch1, 
cyclin D1, c-Myc, vascular endothelial growth factor, Bcl-
2, and snail, depending upon cell type46 and degradation of 
the repressor transcription factor Gli3. Depending on the 
Gli2 posttranscriptional and posttranslational processing 
events, Gli2 has been shown to act as either a positive or 
negative regulator of Hh pathway signaling.47 Deregulated 
Hh signaling has been associated with either mutations in 
pathway genes or overexpression of signaling molecules 
in either tumor cells themselves or in cells within the 
supportive tumor microenvironment.46,48–51
The first link between the Hh pathway and BCC came 
from the discovery of loss-of-function mutations of 
Ptch1 gene in Gorlin syndrome.29,52 Patients with Gorlin 
syndrome are strongly predisposed to the development of 
BCC at an early age. Recent molecular and genetic studies 
have shown that almost all BCC tumors contain genetic 
alterations in components of the Hh signaling pathway 
and these tumors have elevated Ptch and Gli1 messenger 
(m)RNA levels.53,54 This ligand-independent mechanism 
of Hh activation, driven by specific Hh gene mutations 
within the tumor cells, is termed Type I Hh signaling.46 It 
has been estimated that almost 90% of sporadic BCCs have 
loss-of-function mutation in at least one allele of Ptch1 
and in addition, around 10% have activating mutations in 
the SMO, rendering it resistant to Ptch1 inhibition.28,55–57 
In contrast, mutations in other downstream molecules 
of the Hh pathway appear to be rare in BCC. In a study 
of 42 patients with sporadic BCC, only two patients had 
mutations in SUFU, one of which was a missense mutation 
and the other a silent mutation.58 No mutation was seen 
in Gli1.
Pharmacology of vismodegib
Structure
Vismodegib is an orally active SMO inhibitor (2-chloro-
N-[4-chloro-3-pyridin-2-yl-phenyl]-4-methanesulfonyl 
benzamide) with a molecular weight 421.30 g/mol 
(Figure 2).
Preclinical evidence
Vismodegib was shown to be effective in suppressing Gli in 
the Hh responsive tumor cell line CALU-6 when implanted 
in nude mice.59 It was also effective in producing complete 
regression of the Hh pathway dependent medulloblastoma 
allograft model generated from Ptch?/? mice.59
Pharmacokinetics
Vismodegib has an unusual pharmacokinetic profile. It 
demonstrates saturable absorption with a dose dependent 
increase in absorption until a dose of 540 mg, beyond which 
the degree of absorption does not appear to increase.60 This 
could explain the plateau of the rise in concentration of the 
drug within the first 14 days. The drug reaches its steady 
state concentration in the plasma in about 7–14 days after 
initiation of therapy. Vismodegib is highly protein bound to 
albumin and ?
1
-acid glycoprotein. Plasma concentrations 
of total vismodegib appear to be strongly correlated with 
?
1
-acid glycoprotein levels.60,61 Food does not seem to affect 
the degree of absorption of vismodegib.
Vismodegib undergoes oxidation mediated by 
the cytochrome P450 (CYP) enzymes CYP2C9, 
CYP3A4, and CYP3A5, and the oxidative metabolites 
are excreted in the feces.62,63 In addition, vismodegib 
undergoes glucuronidation and pyridine ring cleavage 
to a smaller extent.62 A study in dogs and rats found that 
a small proportion of the drug was metabolized by an 
uncommon pyridine ring opening.64 These metabolites 
were excreted in the feces as well. In pharmacokinetic 
studies, vismodegib had an elimination half-life of 
approximately 12 days after a single dose. However this 
duration decreased to 4 days after repeated, once-daily 
administration, suggesting an increased clearance with 
repeated administration.65
Cl
NH
N O
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SO2Me
Figure 2 Chemical structure of vismodegib.
Note: Structure of vismodegib is courtesy of Genentech.
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Although it has not been specifically studied, based on the 
pharmacokinetic profile, it is unlikely that renal dysfunction 
affects the safety profile of vismodegib significantly. Hence, 
patients with renal dysfunction are not likely to need a 
modification of their dose. The need for dose modification in 
patients with hepatic dysfunction is currently unknown.
Pharmacodynamics
Vismodegib binds to, and inactivates, SMO. This prevents 
its translocation when Ptch1 is stimulated by Hh ligands and 
leads to the inhibition of the downstream signaling pathways 
and a decrease in the production of downstream proliferation 
factors (Figure 1).66
Exposure to vismodegib leads to the downregulation 
of Gli1. In a Phase I trial of vismodegib in patients 
with locally advanced or metastatic solid tumors there 
was ?2 fold downmodulation of Gli1 expression in 
skin biopsies from almost 75% patients, compared with 
pretreatment specimens.66 In the same study, a similar 
proportion of patients with BCC showed ?2 fold down-
modulation of Gli1 expression. However, the down-
modulation of Gli1 expression was not associated with 
plasma concentrations of the drug.
Adverse effects
Vismodegib is relatively well tolerated. The most common 
adverse reactions seen in clinical trials have been muscle 
spasms (70%), alopecia (60%), dysgeusia (55%), weight 
loss (45%), fatigue (40%), nausea (30%), diarrhea (30%), 
decreased appetite (25%), constipation (20%), arthralgias (15%), 
vomiting (12%), and ageusia (10%).67 Approximately 30% 
of premenopausal women developed amenorrhea while on 
vismodegib. Other laboratory abnormalities noted by patients 
on clinical trials included hyponatremia (4%), hypokalemia 
(1%), and azotemia (2%). A recent report described the 
development of keratoacanthomas in two patients, who did 
not have a history of previous squamous cell carcinomas, 
while being treated with vismodegib.68 While the authors were 
not able to establish a causal relationship with vismodegib, 
clinicians need to be alert to these findings.
The vismodegib package insert contains a black box warning 
regarding the risk of severe birth defects and embryonic fetal 
death. This is based on rat studies, which demonstrated that 
vismodegib administered at a dose of 10 mg/kg/day showed 
teratogenic effects.69 This dose corresponds to an exposure of 
approximately 20% of the human exposure at the recommended 
dose of 150 mg daily. Similarly, there is a potential risk of 
exposure to the drug through semen. Hence, sexually active 
individuals receiving vismodegib should be advised of the need 
for contraception (Source: Erivedge™ package insert. http://
www.gene.com/download/pdf/erivedge_prescribing.pdf).
Drug resistance
Resistance mechanisms to vismodegib have not been 
extensively studied, which is understandable given the 
relatively short clinical experience with this drug. However, 
anecdotal reports of acquired resistance to vismodegib are 
beginning to emerge. In the only case reported thus far, 
a 26 year old man with treatment refractory metastatic 
medulloblastoma who was treated with vismodegib responded 
initially, but developed progressive disease after 3 months, 
suggesting the development of resistance. A molecular 
analysis of the biopsy specimen obtained at disease 
progression showed a heterozygous G to C missense mutation 
at position 1697, which is responsible for a change in codon 
473 from aspartic acid to histidine (D473H).70 This mutation 
prevents the binding of vismodegib to SMO, thereby leading 
to resistance.
This was further studied in vitro by Dijkgraaf et al who 
replaced the aspartic acid at position 473 of the SMO gene 
with every other amino acid and found that vismodegib 
did not bind to SMO in any of the mutant variations, 
thereby suggesting that D473 is critical for SMO binding 
by vismodegib.71 It is unclear, however, if D473 is directly 
involved in the binding of vismodegib or if its main role is to 
maintain the necessary SMO conformation for binding.
Other potential resistance mechanisms identified in vitro 
include mutations at E518.71 Substitution of glutamic acid 
at this site conferred complete resistance to vismodegib. 
Other possible mechanisms of resistance include focal 
amplifications of the transcription factor Gli2 and the target 
gene Ccnd1, which exert their actions downstream of SMO.71 
There are initial data on resistance to vismodegib in BCC, 
which are described below.
Mechanisms to overcome this resistance are currently 
being studied. Dijkgraaf et al71 screened multiple chemically 
diverse Hh pathway inhibitors and were able to identify 
several compounds that were active against the two known 
SMO resistance mutations, SMO-D473H and SMO-E518K. 
Available data also suggest that Hh pathway resistant 
medulloblastoma allografts may respond to inhibition of 
phosphoinositide-3-kinase.71
Clinical data on vismodegib
The Phase I trial of vismodegib included 68 patients with 
different malignancies, of which 33 had advanced BCC.66 
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Vismodegib was well tolerated with only six patients 
(8.8%) developing grade 4 adverse events (hyponatremia, 
fatigue, pyelonephritis, presyncope, resectable pancreatic 
adenocarcinoma, and paranoia with hyperglycemia). 
A maximum tolerated dose was not reached and based on 
achievement of maximal plasma concentration and response, 
the recommended Phase II dose was 150 mg daily. Interestingly, 
20 patients (19 with BCC and one with medulloblastoma) had 
a response based on Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria.72 At the time of publication, the 
median duration of response in patients with advanced BCC 
was 12.8 months (range 3.7–26.4 months). This led to further 
investigation of vismodegib in BCC.
A multicenter, international, two cohort, nonrandomized 
Phase II study, administered 150 mg of oral vismodegib daily 
to patients with either metastatic or locally advanced BCC 
(inoperable disease or for whom surgery was inappropriate, 
ie, multiple recurrences and a low likelihood of cure, or 
substantial anticipated disfigurement).73 The response 
rate was 30% for patients with metastatic BCC and 43% 
(21% complete response) in patients with locally advanced 
BCC. The median duration of response was 7.6 months in 
both cohorts. The most common adverse events were muscle 
spasms, alopecia, dysgeusia, weight loss, and fatigue. Serious 
adverse events were reported in 25% of patients. Seven deaths 
were reported, although their relationship to the study drug 
was unclear. The results of these studies led to the approval of 
vismodegib for the treatment of metastatic BCC and locally 
advanced BCC in patients who are not candidates for surgery 
or radiation based on the location or size of the lesion.
More recently, vismodegib has been studied for its 
potential to prevent the development of BCC in patients 
with basal cell nevus syndrome. In a randomized placebo 
controlled trial, 42 patients with the basal cell nevus 
syndrome were randomly assigned to either vismodegib 
(150 mg daily) or placebo for 18 months.74 The primary 
end point of this study was the rate of development of new 
BCC that were eligible for surgical resection. Vismodegib 
significantly reduced the rate of new surgically eligible basal 
cell carcinomas when compared to placebo (2 versus 29 new 
surgically eligible BCC per group annually; P ? 0.001). 
Vismodegib also reduced the size of existing BCC (median 
decrease 71%) when compared to placebo (median decrease 
21%; P ? 0.003). Patients receiving vismodegib had fewer 
surgeries for BCC (mean of ?0.31), compared with those 
receiving placebo (mean ?4.4; P ? 0.001). Palmar and plantar 
pits, pathognomonic signs of the basal cell nevus syndrome, 
also disappeared with vismodegib. However, almost half of 
the patients had to discontinue treatment due to drug related 
adverse events.
Recently, an interesting phenomenon of tumor regrowth 
was reported in patients treated with vismodegib.75 In 
a retrospective analysis of 28 patients on vismodegib, 
Chang et al noted tumor regrowth within or adjacent 
to (?1 cm) the prior tumor bed in 6 (21%) patients.75 
Surprisingly, none of the eight patients with metastatic 
BCC in their analysis demonstrated regrowth after initial 
shrinkage. Hence, close clinical examination of patients, 
even examination of those who have a response to therapy, is 
warranted to detect the development of secondary resistance 
to vismodegib. These findings would also suggest that 
vismodegib and other agents targeting the Hh pathway are 
unlikely to cure BCC, and surgery still would be considered 
the best curative option for patients who can undergo the 
procedure without major cosmetic deformity.
Conclusion
The Hh pathway is critical to the development of BCC. 
Mutations in this pathway are seen in virtually all patients 
with BCC. Inhibition of this pathway with the SMO inhibitor, 
vismodegib, leads to significant responses in patients with 
metastatic and locally advanced BCC. While vismodegib can 
delay the development of BCC in patients with the basal cell 
nevus syndrome, its adverse effect profile tempers its use in this 
setting. Finally, there are reports of resistance to vismodegib 
and those mechanisms are currently being studied.
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